Author Details

Scroll

Refine your search

Collections

Medical Collection

Co-Authors

Journals

Research Journal of Pharmacology and Pharmacodynamics

Year

2022

Authors

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Jain, Ritik. S.

Depression: As a Risk Factor for Coronary Heart Disease

Abstract Views :141 | PDF Views:0

Authors

Marathe Varsha S. ¹, Azam Z. Shaikh ¹, S. P. Pawar ¹, Ritik. S. Jain ¹

Affiliations
1 Department of Pharmacology, P.S.G.V.P.M’s College of Pharmacy, Shahada. Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha, IN

Source

Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 3 (2022), Pagination: 139-145

Abstract

We conducted a review to resolve whether there is relationship between depression and coronary heart disease or not. Depression is a mental health problem which is spread widely and most of physicians are well acquainted with this concept of depression. Diagnosis of depression disorder based on continuity of illness, etiology of illness and number of symptoms - all these discriminations should be reported during inspecting the link between depression and coronary heart disease. We review the mechanism of linking depression and coronary heart disease i.e. relationship between depression and inflammation, depression and autonomic dysfunction, CHD and autonomic dysfunction, depression and Sleep architecture disruption, depression and circadian rhythm disruption, CHD and circadian rhythm disruption, and depression and behavioral mechanism. There is bidirectional association between depression and coronary artery disease i.e. coronary artery disease can cause major depressive disorder and depression is risk factor for CAD and its complications. Major depression is a devastating comorbid disease that can make recovery difficult and increase risk of cardiac mortality and morbidity. We also go over the therapy options like Psychotherapy, Electroconvulsive therapy, Exercise etc. But there are some antidepressant medications also available for treating depression in patients associated with CAD. The antidepressant medications like SSRIs e.g. Sertraline, fluoxetine, citalopram etc. appears to be safe in individual with depression and concomitant CAD or unstable angina. However, some evidence suggests that SSRIs like tricyclics, may increase risk cardiac events and death when taken for long time. New classes of antidepressants have dual reuptake inhibition for serotonin and nor-epinephrine e.g. venlafaxine. These medications are slightly more successful than SSRIs in treating depression, but they also have some adverse effects. Selegiline transdermal form was recently licensed for the treatment of MDD. Oral selegiline is not effective antidepressant. When compared to oral selegiline, STS results in stable plasma levels of drug and increased drug concentration in the brain.

Keywords

Coronary heart disease, Depression, CAD, Venlafaxine.

Full Text

References

Cassem H, Hackett TP, psychiatric consultation in coronary care unit, Ann Intern Med 1971(75),9-14.

Cay EL, Vetter N, Philip AE, Dugard P, psychological status during recovery from acute heart attack, J Psychosom Res 1972(16), 425-435.

Croog SH, Levine S, life after Heart Attack, New York Human sciences press Inc., 1982.

S. Moussavi, S. Chatterji, E.Verdes, A. Tardon, V. Patel, and B. Ustun, “Depression chronic disease and decrements in healthhealth; results from world Health surveys,” Lancet 2007 (370), no. 9590, pp. 851-858,

Lichtman JH, Froelicher ES, Blumenthal JA, carney RM, Doering LV, Frasuresmith N, Freedland KE, Jaffe AS, Leifheit - Limson EC, sheps DS, Vaccarino V, Wulsin L, American Heart Association Statistics Committee Of Council On Epidemiology and prevention and council on cardiovascular and Stroke Nursing Depression as risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations,a scientific statement from American Heart Association circulation 2014 (129),1350-1369.

Vaccarino V. Bremner JD, Behavioral, emotional and neurobiological determinants of coronary heart disease risk in women, Neurosci Blobehav Rev 2017 (74), 297-309.

D. Lloyd-Jones, R.J. Adams, T.M. Brown et al, “Heart disease and stroke statistics-2010 update,a report from American Heart Association”, Circulation 2010 (121), no.7, pp. e46-e215.

R.M. Carney and K.E. Freedland, “Depression in patients with coronary heart disease”, American Journal of Medicine 2008 (121), no. 11, Supplement, pp. S20-S27.

D.E. Bush, R.C. ziegelstein, U.V. Patel et al, “post myocardial infarction depression”, Evidence Report / Technology Assessment 2005,no. 123, pp. 1-8.

J.P. Van Melle, P. De Jonge, T. A. Spijkerman et al, “prognostic association of depression following myocardial infarction with mortality and cardiovascular events, a meta-analysis,” Psychosomatic Medicine 2004 (66), no.6, PP. 814-822.

N.Frasure- Smith and F. Lesperance, “Reflection on depression as a cardiac risk factor”, Psychosomatic Medicine 2005 (67), Supplement 1, PP.S19-S25, 2005.

American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.

Penninx BW, Depression and cardiovascular disease, epidemiological evidence on their linking mechanisms, Neurosci Biobehav Rev 2017 (74), 277-286.

W.M.MCDonald, I. H. Richard, and M.R.Delong, “prevalence, etiology and treatment of depression in Parkinson’s disease,” Biological Psychiatry 2003 (54), no.3, pp.363-375.

H. A Pincus, W. W. Davis, and L.E.Mcqueen, “subthreshold” mental disorders, a review and synthesis of studies on minor depression and other “brand names” British Journal of Psychiatry 1999 (174), pp. 288-296.

16 W.E. Broadhead, D. G. Blazer, L.K. George, and C.K. Tse, “Depression disability days, and days lost from work in prospective epidemiologic survey,” Journal of American Medical Association Association 1990 (264),no. 19, pp. 2524-2528.

I. B. Hickie, G. Andrews, and T. A. Davenport, “Measuring outcomes in patients with depression or anxiety: an essential part of clinical practice,” Medical Journal of Australia 2002 (177), no. 4, pp. 205-207.

M.E. Maruish, “Handbook of psychological assessment in primary care settings," in Handbook of psychological assessment in primary care settings, Lawrence Erlbaum 2000 Mahwah, NJ, USA.

Mason JC, Libby P, Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36:482-9c.

L. M. Biasucci, “CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in a patients with cardiovascular diseases: a background paper,” Circulation 2004 (110),no. 25, pp. e560-567.

N. H. Wallen, C. Held, N. Rehnqvist, and P. Hjemdahl, “Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction,” European Heart Journal 1999 (20), no. 14, pp. 1039-1043.

N. T. Mulvihill, J. B. Foley, R. T. Murphy, R. Curtin, P. A. Crean, and M. Walsh, "Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules,” Heart. 2001 (85), no. 6, pp. 623-627.

P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” New England Journal of Medicine. 2000 (342), no. 12, pp. 836-843.

R. M. Carney, K. E. Freedland, R. C. Veith et al., “Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease,” Biological Psychiatry 1999 (45), no. 4, pp. 458-463.

H. W. Koenigsberg, M. H. Teicher, V. Mitropoulou et al., “ 24 h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression,” Journal of Psychiatric Research 2004 (38), no. 5, pp. 503-511.

R.C. Veith, N. Lewis, O.A. Linares et al., “Sympathetic nervous system activity in major depression: basal and desipramineinduced alterations in plasma norepinephrine kinetics,” Archives of General Psychiatry 1994 (51), no.5, PP. 411-422.

P. W. Gold, M. L. Wong, D. S. Goldstein et al., “Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia,” Proceedings of the National Academy of Sciences of the United States of America. 2005 (102), no. 23, pp. 8303-8308.

P. J. Schwartz, “The autonomic nervous system and sudden death,” European Heart Journal. 1998(19), pp. F72-F80.

N. P. Andrews, D. S. Goldstein, and A. A. Quyyumi, “Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects,” American Journal of Cardiology.1999 (84) no. 3, pp. 316-320.

R. M. Benca, W.H obermeyer, R.A. Thisted, J.C.Gillin, D.J.Kupfer, and C.F. Reynolds, “sleep and psychiatric disorders: a meta-analysis,” Archives of General Psychiatry. 1992 (49), no.8, PP. 651-670.

U. John, C. Meyer, H.J. Rumpf, and U. Hapke, “ Relationships of psychiatric disorders with sleep duration in an adult general population sample,” Journal of Psychiatric Research. 2005 (39), no. 6, pp. 577-583.

C.F.Reynolds and D. J. Kupfer, “sleep research in affective illness: state of the art circa 1987,”sleep 1987 (10), no.3, pp.199-215.

D.J. Kupfer and M.E. Thase, “The use of the sleep laboratory in diagnosis of affective disorders,” Psychiatric Clinics of North America. 1983 (6), no.1, PP. 3-25.

J. shen, S. A. Chung, L. Kayumov et al., “polysomnographic and symptomatological analysis of major depressive disorder patients treated with mirtazapine,” Canadian Journal of Psychiatry. 2006 (51), no. 1, PP. 27-34.

D. Kunz and W. M. Herrmann, “Sleep-wake cycle, sleep-related disturbances, and sleep disorders: a chronobiological approach,” Comprehensive Psychiatry 2000 (41), no. 2, Supplement 1, pp. 104-115.

D. H. Avery, S. H. Shah, D. N. Eder, and G. Wildschiedtz, “nocturnal sweating and temperature in depression,” Acta Psychiatrica Scandinavica. 1999 (100), no. 4, pp. 295-301.

D. H. Avery, G. Wildshiodtz, and O. J. Rafaelsen, “Nocturnal temperature in affective disorder,” Journal of Affective Disorders. 1982 (4), no. 1, pp. 61-71.

W. C. Duncan Jr., “Circadian rhythms and the pharmacology of affective illness,” Pharmacology and Therapeutics. 1996 (71), no. 3, pp. 253-312.

E. Souetre, E. Salvati, J. L Belugou et al., “Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality,” Psychiatry Research. 1989 (28), no. 3, pp. 263-278.

E. Souetre, E. Salvati, T. A. Wehr, D. A. Sack, B. Krebs, and G. Darcourt, “Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects,” American Journal of Psychiatry. 1998 (145), no. 9, pp. 1133-1137.

M. P. Szuba, B. H. Guze, and L. R. Baxter, “Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects,” Biological Psychiatry. 1997 (42), no. 12, pp. 1130-1137.

L. Wetterbuerg, J. Beck-Friis, B. Aperia, and U. Petterson, “Melatonin/cortisol ratio in depression,” Lancet. 1979 (2), no. 8156-8157, article 1361.

J. Arendt, A. Wirz-Justice, J. Bradtke, and M. Kornemark, “Longterm studies on immunoreactive human melatonin,” Annals of Clinical Biochemistry. 1979 (16), no. 6, pp. 307-312.

J. Mendlewicz, P. Linkowski, L. Branchey, U. Weinberg, E. D. Weitzman, and M. Branchey, “Abnormal 24 hour pattern of melatonin secretion in depression,” Lancet. 1979 (2), no. 8156- 8157, article 1362.

M. C. Cohen, K. M. Rohtla, C. E. Lavery, J. E. Muller, and M. A. Mittleman, “Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death,” American Journal of Cardiology. 1997 (79), no. 11, pp. 1512-1516.

J. E. Muller, P. H. Stone, and Z. G. Turi, “Circadian variation in the frequency of onset of acute myocardial infarction,” New England Journal of Medicine. 1985 (313), no. 21, pp. 1315-1322.

R.M. carney, K.E. freedland and A.S. Jaffe, “Altered circadian pattern of acute myocardial infarction in patients with depression,” Coronary Artery Disease. 1991 (2), no. 1, pp. 61-65.

P. M. Ho, J. A. Spertus, F. A. Masoudi et al., “Impact of medication therapy discontinuation on mortality after myocardial infarction,” Archives of Internal Medicine. 2006 (166), no. 17, pp. 1842-1847.

J. N. Rasmussen, A. Chong, and D. A. Alter, “Relationship between adherence to evidence-based pharmacotherapy and longterm mortality after acute myocardial infarction,” Journal of the American Medical Association. 2007 (297), no. 2, pp. 177-186.

I. M. Kronish, N. Rieckmann, E. A. Halm et al., “Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes,” Journal of General Internal Medicine. 2006 (21), no. 11, pp. 1178-1183

B. K. Nallamothu, K. A. A. Fox, B. M. Kennelly et al., “Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events,” Heart. 2007 (93), no. 12, pp. 1552-1555.

Spijkerman TA, van den Brink RH, Jansen JH, et al. Who is at risk of post-MI depressive symptoms? J Psychosom Res. 2005 (58), 425-432.

Pratt LA, Ford DE, crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: Prospective data from the Baltimore ECA follow-up. Circulation. 1996 (94), 3123- 3129.

Lesperance f, Frasure- Smith N, Talajic M Major depression before and after myocardial infraction: its nature and consequences. Psychosom Med. 1996 (58), 99-110.

Lauzon C, Beck CA, Huynh T et al. Depression and prognosis following hospital admission because of acute myocardial infarction. CMAJ. 2003(108), 547-552.

Rumsfeld JS, Jones PG, Whooley M, et al. Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J. 2005 (150), 961-967.

Tridevi MH, Fava M, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006 (163), 28-40.

Glassman AH, O’Connor CM, califf RM,et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002 (288),701-709.

Swenson JR, O’Connor CM, Barton D, et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol. 2003 (92),1271-1276.

Whang W. Kubzansky LD, Kawachi I, Rexrode KM. Kroenke CH, Glynn RJ, Garan H, Albert CM. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol 2009 (53), 950-958.

Weeke P. Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosbol EL, Larsen JK, Lippert FK, Nielsen SL, Gerds T, Andersen PK, Kanters JK, Poulsen HE, Pehrson S, Kober L, TorpPedersen C. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 2012 (92), 72-79.

Patkar AA, Pae CU, Masand Ps. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS spectr: 2006 (11), 363-375.

Halper JP, Mann J. cardiovascular effect of antidepressants medication Br J Psych.1988; (Suppl):87-98.

Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease Psychosom Med 2013 (75), 335-349.

Blumenthal JA, sherwood A, smith PJ, Watkins L, Mabe S, Kraus WE, Ingle K, Miller P, Hinderliter A. Enhancing cardiac rehabilitation with stress management training: a randomized, clinical efficacy. Circulation. 2016 (133), 1341-1350.

AIDS: The Long term disease

Abstract Views :172 | PDF Views:0

Authors

Sakshi. B. Chaudhari ¹, Harsha. S. Suryawanshi ¹, Azam Z. Shaikh ¹, S. P. Pawar ¹, Ritik. S. Jain ¹

Affiliations
1 Department of Pharmacology, P.S.G.V.P. M’s College of Pharmacy, Shahada. Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha., IN

Source

Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 3 (2022), Pagination: 155-158

Abstract

The world stands for Acquired immunodeficiency syndrome. The public understanding of AIDS as a highly critical acute illness with a rapid downward trajectory was crystallized nevertheless. In that some of advanced stages of that disease. Many countries has allowed AIDS to reach catastrophic level. AIDS is effect on mental state of injected person. The person may undergo depression. The mental health could be improved by acquisition of social support like friends and family. Provide helpful links like education, health care and social support. AIDS is sexually transmitted disease. It can be spread through person to person. AIDS is responsible for behaviour changes. Research has worked hard to compreshed the AIDS epidemic since its inception nature of the disease and its manifestation. The human immunodeficiency virus (HIV) is the causative agent (HIV). The two of them HIV-1 and HIV-2 are the most common type of HIV. The three diploid single stranded RNA genomes protease, reverse transcriptase, and viral enzyme integrates. AIDS does not have a cure. The greatest choice is prevention. Infection in blood transfusion patients of course, is a new-born (from mother). It is a malady that can only be tackled, by the social and mental fraternity acting together, to prevent the spread of the disease. There are significant continuities as well as discontinuities in the experience of living with HIV/AIDS during the last two decided, as this reveals release. The aids are sexually transmitted disease.

Keywords

HIV/AIDS, Immunodeficiency, lentiviruses.

Full Text

References

Siegel K, krauss B. Living with HIV infection: adaptive task of seropositive gay men. J Health SocBehav 1991, 32: 17-22.

Nokes k. Applying the chronic illeness trajectory model to HIV/AIDS. Such InqNuts pract 1991, 5: 197-204.

Jeu S. Psychosocial issues of AIDS long term survivors. Families Soc 1994, 75: 324-334.

Kobayashi, JS. The evolution of adjustment issue in HIV/AIDS. Bull menningerclin 1997, 61 (2.): 146-38.

Rabkin JG, ferrando S. A second life agenda: Psychiatric research issue raised by protease inhibitors treatment for people with the human deficiency virus or acquired immunodeficiency syndrom. Arch Gen psychiatry 1997, 54: 1049-1053.

Sowell RL, Philips KD, Grier J. Restructuring life to face the future: the perspective of men after a positive response to protease inhibitor therepy. AIDS patients care STDS 1998, 12: 33-42.

Centers for Disease control and prevention. update: trends in AIDS incidence- united state, 1996 Morbid Mortal WKly Rep 1997, 46: 861-867.

UNAIDS, WHO. Under Embargo. AIDS Epidemic update joint united Nation, programme on HIV/ AIDS (UNAIDS) and world health organisation (WHO). Geneva: December 2001.

Bassetti s, Battegay M, further H. et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? SWISS HIV cohort study. J acquire immune Deficsyndr 1999, 21: 114-119.

Maisels L, Steinberg J. Tobaisc. An investigation of why eligible patients do not receive HAART AIDS patient care 2001, 15: 185- 191.

Herbert, B, Brownstone A, clanon K, Abercrombie P, Bangberg D. Combination anti-retroviral therapy: health care providers confront emerging dilemmas. AIDS care 2000, 12: 409-421.

Chesney MA, ICKOVICS J, Hecht FM, Sikia G, Rankin J. Adherence: a necessity for successful HIV combination therapy. AIDS 1999, 13 (SUPPLA): s271-s278.

Fogarty L, Roter D, Larson S, Burkaj, Gillespie J, levy R. Patients adherence to HIV medication regimens: a review of published and abstract reports. Patient Edvc coins 2002, 46: 93-108.

Cook JA, Cohen MH, Grey D, et al. Use of highly active antiretroviral therapy in a cohort of HIV seropositive Women. Am J public Health 2002, 92: 82-87.

Jacobson LP, Gore ME, strathdee SA, phair JP, Riddler's, Detels R. Therapy naivete in the era of potent anti-retroviral therapy. J club Epidemial 2001, 54: 149-156.

Jeffe DB, Meredith KL, Mindy LM, Fraser VJ. Factors associated with HIV infected patients recognition and use of HIV medication. J acquir immune Deficsyndr Hum Retrovir 1998, 19: 359-360.

Mocroft A, Gill MJ, Davidson W, Philips AN. Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care? J Acquir immune Deficsyndr 2000, 24: 475-482.

Atklnson, J. H and Grant, I.(1994). Natural history of neuropsychiatric manifestation HIV disease. Psychiatric clinics of North America 17, 17-23.

HART, J, Einav, C, Weingarten, M.A and Stein, M (1990). the important of family support in a behaviour modification weight loss program. Journal of America Dietic association, 90, 1270- 1271.

Sturat, R.B and DAVIS, B. (1972). slim chance in a fat world. Chicago, IL: Research press.

Wilcox, D.R.C., GILLAN, R and HARE, E.H (1965). do Psychiatric outpatient take their drugs? British Medical Journal,22, 790-792.

Nokes K. Revisiting how the chronic illness Framework can be applied to people living with HIV/ AIDS.schlnq Nuts pract 1998, 12: 27-31.

Bogart LM, Catz SL, Kelly JA. et al. Psychosocial issue in the era of new AIDS treatment from the perspective of person living with HIV.J Health psychol 2000, 5: 500-516.

Schultz MA Sanfort TG. HIV- positive people, risk and sexual behaviour. socsci Med 2000,50: 157-1588.

Barre- Sinoussi F. ChermannJc, Rey F, et al. Isolation of a Tlymphotropicretrovirus from patients risk for Acquir immune deficiency syndromes. Science (1983) 220: 863-70.

Popovic M, Sarngadhan MG, Read E, Gallo Rc, Detection isolation and continuous production of cytopathic retrovirus (HTLV-III) from patient with AIDS and pre AIDS Science 1984; 224: 500-04.

Hayami M, Ido E, minurat T, survey of simian immunodeficiency virus among non- human prvote population. Cure Top Microbial Immunol 1994; 188: 1-20.

Myers G. Maclnnes K, Korber B. The emergence of simian/ human immunodeficiency viruses. AIDS Res Hum Retrovir 1992; 8: 373-85.

Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localisation signal within HIV-1 matrix protein that governs infection of non - dividing cells. Nature 1993; 365: 666-68.

Weiss RA. Cellular receptor and viral glycoprotein involved in retrovirus entry. In :LevyJA, ed. The Retrovirifae, vol3.New York plenum, 1993; 1-108.

Coffin JM. Structure and classification of retrovirus. I n: levy JA, ed the retroviridaevol 1. New York Plenum, 1992: 29-50.

Levy JA. Pathogenesis of human immunodeficiency virus Infections Microbial Rev 1993; 57: 183-289.

Strebel K, Davgherty D, clause K, Cohen D, folks T, Martin MA . The HIV a (SOR) gene product is essential for virus infectivity. Nature 1987; 328: 728-30.

Strebel K, Kimkait T, Martin MA. A novel gene of HIV-1, Vpu and it's 16- kilodalton product. Science 1988; 241; 1221-23.

Bukrinsky MI., Sharova N, Derpsey MP. active nuclear import of human, immunodeficiency virus type 1 proteingration complexes pro Nal-1 Acadsci USA 1992; 89: 6580-84.

Benn S, Ruttedge R, Folks T, et al genomic heterogeneity of AIDS retroviral isolates from north America and Zaire science 1985; 230: 949-57.

Goodenow M, Hurt T, Saurin W, Kwoks, Sninsky J, wain- Hobson S HIV-I isolates are rapidly evolving quasispecies; evidence for viral mixture and preferred nucleotide substitution. J acquire immune Deficsyndr 1989; 2; 344-52.

Cannot RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Viral 1994; 64: 4400-08.

Wei X. Gosh SK, Taylor ME, et al viral dynamic in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117- 22.

Ho DD, Neumann AV, perelson As, et al Rapid turnover of plasma variation and CD4 lymphocytes in HIV-l infection. Nature 1995; 373: 123-26.

Caffin J. Genetic diversity and evolution of retroviuses. Cure topic Microbial Immunol 1992; 176; 143-64.

Chesney MA. factors affecting adherence to anti-retroviral therapy. CL n Infect Dis 2000, 30(suppl2): s 171-s 176.

D' ArminioMonteforte A, lepri AC, Rezza G, et al. Insight into the reason of discontinuation therapy (HAART) regimen in a cohort of anti-retroviral naive patients I.CO.N.A. studygroup. italian cohort of anti-retroviral naive patients. AIDS 2000,14: 499-507.

Gold RS, Hinchy J, Batrouney CG. The reasoning behind decision not to take up anti-retroviral therapy in Australian infected with HIV. Int STD AIDS 2000,11: 361-370.

Izopet J, Massip P, Sourish, et al. Shift in HIV resistance and short term antiviral effect following a new salvage regimen. AIDS 2000, 14: 2247-2255.

Maggiolo, F, Callengaro A, Gregis G, et al. Strategic selective treatment in highly pre- treated HIV patients harbouring multiply resistant virus. AIDS 2002, 16: 289-299.

kelly JA, otto - Salaj LL, sikkema KJ, pinkerton SD, Bloom FR. Implications OF HIV treatment advances For behavioral research on AIDS protease inhibitors and the new challenges. in HIV primary prevention. Health Psycho" 1998, 17: 310 319.

Selwyn P, Arnold R. from fate to tragedy: the changing meanings of life death and AIDS, Ann Intern Med 1998, 129: 899-902.

Mind, C. and white D. O (1984) viral pathogenesis and Immunology (Blackwell, Oxford).

Fvans A.S. (1989) J. Acquired Immune Deficiency -syndr 2, 107 - 113.

Duesberg, P.H. (1989) J. Acquired Immune Deficsyndr 2, 514- 517.

Cancer: Immunology and Immunotharapy

Abstract Views :132 | PDF Views:0

Authors

Saloni S. Chhajed ¹, Mayuri V. Mali ¹, Azam Z. Shaikh ¹, S. P. Pawar ¹, Ritik. S. Jain ¹

Affiliations
1 Department of Pharmaceutics P.S.G.V.P.M’s College of Pharmacy, Shahada., IN

Source

Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 3 (2022), Pagination: 159-164

Abstract

During immune surveillance, the host provides defense versus foreign antigens. By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. The use of antibodies to woodcut pathways inhibiting the endogenous immune response to cancer, known as checkpoint tampon therapy, has stirred up a unconfined deal of excitement among scientists, physicians, and patients alike. Clinical trials evaluating the safety and efficacy of antibodies that woodcut the T lamina inhibitory molecules cytotoxic T-lymphocyte various kinds of immunotherapy treatment for cancer are either misogynist to the public or are in the process of clinical trials. Immunotherapy treatments have the potential to treat cancer with significantly less toxicity than chemotherapy and radiation treatments. An accent on cellular infusion as a method of either enhancing the immune system by creating an environment for se-questering the host immune system to wade cancer cells or increasingly directly inserting cells to di-rectly wade cancer cells will be provided in this review. Various forms of cancer vaccines are moreover discussed in this paper as an important speciality in immunotherapy. This review seeks to describe various methodologies associated with overseeing immunotherapy in the treatment of cancer

Keywords

Cancer, Checkpoint tampon therapy, T-lymphocyte.

Full Text

References

Gravitz L. Cancer Immunotherapy. Nature. 2013; 504: S1 2. Palucka K. Q&A: Evidence presenter. Interview by Marian Turner. Nature. 2013; 504: S9. 60

Palucka K. Q&A: Evidence presenter. Interview by Marian Turner. Nature. 2013; 504: S9

Humphries C. Adoptive cell therapy: Honing that killer instinct.Nature. 2013; 504: S13-5.

Weintraub K. Drug development: Releasing the brakes. Nature. 2013; 504: S6-8

Littman DR. Releasing the brakes on cancer immunotherapy. Cell. 2015; 162: 1186-90.

Hodi FS, O’Day SJ, Mc Dermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015; 36: 265-76upon programmed cell death. EMBO J. 1992; 11: 3887-95.

Fialkow PJ. Clonal origin of human tumors. Biochim Biophys Acta. 1976; 458: 283-321.

Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977; 197: 893-5.

Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194: 23-8.

Mueller MM, Fusenig NE. Friends or foes — bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4: 839-49.

Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006; 355: 1253-61.

Cohnheim J. Congenitales, quergestreiftes Muskelsarkom der Nieren. Path Anat Physiol Klin Med. 1875; 65: 64-9.

Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea — a paradigm shift. Cancer Res. 2006; 66: 1883-90.

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-7.

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, CaceresCortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8.

Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013; 123: 1911-8.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009; 361: 2449-60.

Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10: 13-27.

Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011; 60: 116-29.

Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1157-66.

Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009; 20: 1071-82.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-8.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554.

Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-13.

Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358: 1148- 59.

Piccart-Gebhart MJ, Procter M, Ley land-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659- 72.

Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997; 3: 2703-7.

Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005; 23: 3235-42.

Kim ES, Vokes EE, Kies MS. Cetuximab in cancers of the lung and head & neck. Semin Oncol. 2004; 31 [Suppl 1]: 61-7.

Finn OJ. Cancer Immunology. N Engl J Med. 2008; 358: 2704-15.

Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7: 95-106.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab [anti-PD-1] in melanoma. N Engl J Med. 2013: 369: 134-44.

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; 33: 1889-94.

Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011; 10: 101-11.

Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012; 148: 1081-4.

Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007; 13: 5133-43

Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Rev Immunol. 2008; 8: 467-77.

Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013; 19: 28-33.

May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin Cancer Res. 2011; 17: 5233- 8.

Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014; 65: 185-202.

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348: 69-74.

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 ; 348: 56-61.

Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994; 1: 405-13.

Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182: 459-65

Deguine J, Breart B, Lemaitre F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8+ T cells during tumor regression. Immunity. 2010; 33: 632-44.

Restivo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12: 269-81.

Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001; 98: 2526-34.

Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976; 193: 1007-8.

Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985; 161: 1169-88.

Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982; 156: 385-97.

Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol. 1984; 132: 2123- 8.

Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, et al. Preclinical evaluation of ex vivo expanded/activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol. 2011; 101: 179-88.

Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007; 82: 1365-74.

Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science. 2001; 293: 251-3.

Reise Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006; 6: 476-83.

Anguile S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy. 2012; 14: 647-56.

Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC, et al. Effector and regulatory events during natural killerdendritic cell interactions. Immunol Rev. 2006; 214: 219-28.

Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010; 33: 464- 78.

Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208: 1989-2003.

Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. 2011; 208: 2005-16.

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol. 2004; 22: 1916-25.

Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007; 67: 1842-52.

Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother. 2006; 55: 85-95.

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol. 2006; 24: 3107-12.

Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6674-81.

Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34[+] progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006; 55: 1209-18.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29: 545-57.

Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with nonresectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer. 2006; 95: 1474-82.

Gould P. Sipuleucel-T shows partial advantage in prostate cancer. Lancet Oncol. 2006; 7: 710.

Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies — outcomes from the 2006 meeting of the Cancer Vaccine Consortium [CVC]. Vaccine. 2007; 25 [Suppl 2]: B97-109

Username
Password
Remember me